Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study

By sjmartinez • May 18, 2025

Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H, Angel B, Li Q, Chen X, Paller AS. Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study. J Am Acad Dermatol. 2025 May 14:S0190-9622(25)02124-3. doi: 10.1016/j.jaad.2025.05.1385. Epub ahead of print. PMID: 40378883.

Tags: atopic dermatitis, children, Dermatology, eczema, efficacy, JAK inhibitor, Janus kinase, pediatric, phase 3, Publications, randomized, ruxolitinib cream, safety, topical

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin[...]

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST

Coates LC, Gladman DD, Merola JF, Mrowietz U, Armstrong A, Baraliakos X, Tillett W, Kishimoto M, Reddy J, Teng L, Amouzadeh H, Deignan C, Mease[...]

GRAPPA 2025 Annual Meeting Report: Session on Geographic Variations in Psoriatic Arthritis/Psoriasis Care and Resource Limitations

Ma EJ, Boit R, Leung YY, Singla S, Fernández-Ávila D, Kalyoncu U, Armstrong AW. GRAPPA 2025 Annual Meeting Report: Session on Geographic Variations in Psoriatic[...]